Drug Database
CE

cefazolin dibenzylamine (Daren)

✓ Approved

Pfizer, Inc. · Small Molecule · Small Molecule

What is cefazolin dibenzylamine?

cefazolin dibenzylamine is a small molecule developed by Pfizer, Inc.. It is approved for therapeutic indications via injectable (others) or intramuscular (im) injection.

Drug Profile

Brand NamesDaren
CompanyPfizer, Inc.
Drug ClassSmall Molecule
RouteInjectable (Others), Intramuscular (IM) Injection
StatusApproved

Therapeutic Indications

cefazolin dibenzylamine is developed for 2 unique indications across 1 therapeutic area.

Therapeutic AreaConditionPhase
Infections and infestationsUrinary tract infection✓ Approved
Infections and infestationsRespiratory tract infection✓ Approved

Related Research Articles

PubMedInternational journal of obstetric anesthesia2026-08-24

Cefazolin administration prior to caesarean delivery and breastmilk microbiome: a nested cohort within a randomised clinical trial.

Eley Victoria V, Martin Elizabeth E, Amoako Akwasi A, Hartel Gunter G et al.

Consistent with guidelines, anaesthetists administer pre-incision cefazolin to patients having caesarean delivery in Australia. These antibiotics may impact the breastmilk microbiome. We hypothesised that the breastmilk microbiome of mothers administered cefazolin would differ from those administered placebo. In this nested cohort within a randomised clinical trial, samples were collected from adult females having caesarean delivery. Patients received cefazolin 2 g in 100 mL normal saline (cefazolin group) or 100 mL normal saline (placebo group) prior to skin incision. Breastmilk samples were collected by participants on post-operative day 14 and 30 and immediately frozen. Microbial composition of samples was assessed via long-read 16S rRNA sequencing. From the cefazolin group, there were 12 samples (day 14) and 13 (day 30). From the placebo group, there were 11 (day 14) and 9 (day 30). Full-length 16S rRNA sequencing yielded sufficient reads to characterise the breastmilk microbiota at both time points. Cefazolin exposure was associated with alterations in the composition, including increased abundances of the aerobic species Roseateles spp. and Cutibacterium acnes and a predominance of Gram-negative taxa. These shifts suggest suppression of Gram-positive commensals. The resulting microbial communities appeared relatively static and enriched with less-characterised, environmentally associated genera, indicating that cefazolin may potentially disrupt normal breastmilk microbial maturation by creating niches preferentially occupied by antibiotic-tolerant taxa. In this small, restricted sample, cefazolin exposure prior to delivery exerted modest effects on the breastmilk microbiome. The clinical implications require further evaluation in a larger, diverse population.

PubMedJSES reviews, reports, and techniques2026-08-23

Zero confirmed allergic reactions to cefazolin in an elective orthopedic cohort with high prevalence of reported beta-lactam allergies.

Balsan Abigail A, Grandberg Camila C, Gilbert Ryan R, Dadoo Sahil S et al.

Cefazolin is the most effective prophylactic antibiotic for orthopedic surgeries. There is a high prevalence of patient-reported beta-lactam antibiotic allergies, which often results in inferior pre-operative antibiotics use. This study's purpose was to determine the rate of true allergic reactions among patients with a reported beta-lactam allergy when administered cefazolin. The hypothesis was that the rate of true allergic reactions would be low following cefazolin administration among patients with reported beta-lactam allergy. Patients undergoing orthopedic surgical procedures by a single surgeon between January 2023 and December 2024 were included. Reported autoimmune/psychiatric disorders, total number of reported allergies, type of reported beta-lactam antibiotic allergy, reported symptoms to beta-lactam antibiotic, and reported allergy severity were obtained via electronic medical records. Allergies were categorized as "true allergies" (anaphylactic/non-anaphylactic) or "other reactions." Demographic and allergy characteristics were compared between patients who did and did not report a beta-lactam antibiotic allergy. Of 1,603 patients (57 ± 18 years; 47% female), 310 (19%) patients reported a beta-lactam antibiotic allergy and 230/310 (74%) specifically reported a penicillin allergy. Female (61% vs. 44%, P < .001) and older patients (60 ± 16 vs. 57 ± 18 years, P = .002) were more likely to report beta-lactam allergies. Of the 310 patients with a reported beta-lactam antibiotic allergy, 18 (6%) patients reported anaphylaxis, 224 (72%) non-anaphylactic reaction, and 100 (32%) reported other reaction type. Of patients with a reported beta-lactam antibiotic allergy, 301 (97%) patients were administered cefazolin during surgery, and 0 patients were found to have a true allergic reaction. Zero patients with a reported beta-lactam antibiotic allergy were found to have a true allergic reaction during the intraoperative or immediate post-operative period following cefazolin administration during an orthopedic surgery. Although reported allergies should be critically evaluated, this suggests cefazolin may be safely administered even if a beta-lactam antibiotic allergy is reported.

PubMedCureus2026-08-21

Timing of Cefazolin Prophylaxis in Clean Surgery: Prophylaxis Administered After Incision Results in a Higher Surgical Site Infection Rate.

Morris Arthur J AJ, Jackways Tanya M TM, Barnett Jane J, Frampton Christopher M CM

The timing of antibacterial prophylaxis in the hour before incision remains undecided because of inadequate clinical outcome data. The purpose of this study was to determine if the timing of cefazolin prophylaxis in the hour before surgery influences the surgical site infection (SSI) rate in clean procedures. We conducted a prospective SSI surveillance in 16 Southern Cross Healthcare hospitals in New Zealand, from 2005 through 2023. The timing of cefazolin antibacterial prophylaxis was recorded, in minutes, with respect to incision time. Patients were followed for 30 days after surgery. Standard definitions for SSIs were used. The SSI rate with respect to the timing of antibacterial prophylaxis was analysed in 10-minute periods. Uni- and multivariable analyses were performed. A total of 52,368 procedures had the timing of prophylaxis recorded in minutes against incision time. There were 694 (1.3%) SSIs. For all procedures, the lowest SSI rate was for prophylaxis given 21-30 minutes before surgery; however, after multivariate analysis, timing within the hour before incision was not significant. Prophylaxis given after incision had a higher SSI rate, with an odds ratio of 1.8 (95% CI: 1.2-2.8, P = 0.01). The SSI rates for prophylaxis increased when cefazolin prophylaxis was given after incision, but no optimal time before incision was observed. The results may not be applicable to non-clean procedures or non-cefazolin prophylaxis.

PubMedFrontiers in public health2026-08-20

Urinary tract infection in urolithiasis patients: risk factor analysis, pathogen distribution, and antimicrobial resistance characteristics.

Yan Lingfei L, He Zhuojie Z, Wang Tao T, Li Qing Q et al.

This study investigated risk factors, pathogen distribution, and antimicrobial resistance characteristics of urinary tract infection (UTI) in patients with urolithiasis. A retrospective analysis was conducted among 934 patients with urolithiasis treated between April 2020 and April 2025. Patients were classified into a UTI group (n = 194) and a non-UTI group (n = 740). Clinical variables, stone-related characteristics, urinary parameters, renal function indicators, urine culture results, and antimicrobial susceptibility data were analyzed. Univariate analysis and multivariate logistic regression were used to identify independent risk factors for UTI. Among 178 non-duplicate pathogenic isolates from the UTI group, Gram-negative bacteria predominated (68.54%), followed by Gram-positive bacteria (27.53%) and fungi (3.93%). Escherichia coli and Pseudomonas aeruginosa were the most common Gram-negative pathogens, while Enterococcus faecalis and Enterococcus faecium were the main Gram-positive pathogens. Escherichia coli showed high resistance to ampicillin, cefazolin, and ceftazidime, whereas no imipenem-resistant Escherichia coli or Pseudomonas aeruginosa isolates were detected. Multivariate logistic regression identified hydronephrosis, urinary tract obstruction, urine pH ≥ 7.0, stone diameter ≥3 mm, and serum creatinine ≥106 μmol/L as independent risk factors for UTI. Urolithiasis-associated UTI is mainly caused by Gram-negative bacteria with notable antimicrobial resistance. Early identification of high-risk patients, timely relief of obstruction, and antimicrobial therapy guided by susceptibility testing may help improve infection management.

PubMedAnnals of clinical epidemiology2026-08-19

Cefazolin Dose-Response-based Correlation of Weight With Orthopaedic Implant-related Surgical-site Infections.

Hatano Masaki M, Sasabuchi Yusuke Y, Yamada Koji K, Aso Shotaro S et al.

This study aimed to evaluate the association of the initial body weight-stratified cefazolin antimicrobial prophylaxis (AMP) dose and surgical-site infection (SSI) in major orthopedic implant surgery. This nationwide, retrospective cohort study used data from the Diagnosis Procedure Combination database. We included patients (age ≥18 years) who underwent major orthopedic implant surgery between July 2010 and March 2022. Patients underwent surgery with an initial cefazolin dose of either 1 g (1 g cefazolin group) or 2 g (2 g cefazolin group). Primary outcome was in-hospital SSI. Restricted cubic spline functions were used to estimate the nonlinear association of body weight-stratified cefazolin dose with the outcome and between cefazolin dose per weight and the outcome. Among the 408,487 participants, 394,731 and 13,756 were in the 1 g and 2g cefazolin groups, respectively. The 1 g cefazolin group, but not the 2 g cefazolin group, showed a J-shaped relationship between body weight and SSI, which increased continuously beyond 50 kg, in an increased risk of SSI with body weight. A reverse J-shaped relationship was observed between cefazolin dose per weight and SSI, with an increased risk of SSI at <20 mg/kg. An increased risk of SSI was observed with 1 g cefazolin, but not with 2 g cefazolin, as an initial AMP with higher body weight among adults weighing >50 kg.

PubMedBone & joint research2026-08-19

Antimicrobial-laden PerOssal beads display in vitro inhibition and killing of extensively drug-resistant Gram-negative bacteria associated with conflict wounds in Ukraine.

Claireaux Henry Adam HA, Douglas Edward J A EJA, Pallett Scott J C SJC, Moore Luke S P LSP et al.

Open fractures sustained in contemporary conflict are associated with high-energy transfer, contamination with resistant bacteria, and delays to surgical care, resulting in high rates of infection. Similar conditions occur in civilian disasters, where crush injuries and overwhelmed healthcare systems prolong the interval to surgical wound excision. Prophylactic systemic antimicrobial regimens may be ineffective due to antimicrobial resistance or limited bioavailability in bone and joint tissues. Local antimicrobial delivery can provide higher drug concentrations within the wound, which may be sufficient to overcome resistance. This route is established in bone and joint infection, although evidence in conflict trauma is lacking. We evaluated the in vitro activity of antimicrobial-laden PerOssal hydroxyapatite and calcium sulphate beads. Bacterial isolates from Ukraine isolated from contaminated traumatic wounds were tested, including extensively drug-resistant (XDR) Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Escherichia coli. The antimicrobial effects of antimicrobial-laden PerOssal beads were assessed by zone-of-inhibition testing and time-kill analysis. All Gram-negative isolates from Ukraine were resistant to gentamicin, tobramycin, co-amoxiclav, cefazolin, and ciprofloxacin, with minimum inhibitory concentrations (MICs) exceeding European Committee on Animicrobial Susceptibility Testing (EUCAST) breakpoints. PerOssal beads laden with gentamicin, tobramycin, or cefazolin were weakly growth inhibitory. However, gentamicin-rifampicin in combination achieved consistent broad-spectrum bacterial inhibition and killing, while co-amoxiclav-loaded beads inhibited the growth of all bacterial strains. Antimicrobial-laden PerOssal hydroxyapatite and calcium sulphate beads displayed in vitro inhibition and killing of XDR Gram-negative bacteria associated with contaminated traumatic wounds. Early local antimicrobial delivery may reduce infection risk following heavily contaminated open fractures, particularly when surgical wound excision is delayed. This may be relevant to both modern conflict and civilian disaster settings. Further work is required to determine the effectiveness of this approach in vivo.

+6254 more articles available with a free account

Sign up free to view all articles →

Ask about cefazolin dibenzylamine